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Abstract
Recent evidence suggests that low vitamin D concentrations are associated with increased levels of inﬂammatory markers. However, there are limited stud-
ies investigating associations between vitamin D levels and inﬂammatory markers in the general population and much of this evidence in older adults is
inconclusive. Therefore, this study investigates the cross-sectional association of serum 25-hydroxyvitamin D (25(OH)D) levels with inﬂammatory markers
in 5870 older English adults from wave 6 (2012–2013) of the English Longitudinal Study of Ageing (ELSA). ELSA is a large prospective observational
study of community-dwelling people aged 50 years and over in England. Serum 25(OH)D levels, C-reactive protein (CRP) levels, plasma ﬁbrinogen levels,
white blood cell count (WBC), age, season of blood collection, waist circumference, total non-pension household wealth, measures of health and health
behaviours that included depression, number of cardiovascular, non-cardiovascular conditions and difﬁculties in activities of daily living, smoking, and
physical activity were measured. There was a signiﬁcant negative association between low 25(OH)D levels (≤30 nmol/l) and CRP (OR 1·23, 95 % CI
1·00, 1·51) and WBC (OR 1·35, 95 % CI 1·13, 1·60) that remained after adjustment for a wide range of covariates of clinical signiﬁcance. However,
for ﬁbrinogen, the association did not remain signiﬁcant when waist circumference was entered in the ﬁnal model. Our ﬁndings showed that 25(OH)
D levels were associated with two out the three inﬂammatory markers investigated. The independent and inverse association between serum 25(OH)D
levels and inﬂammation suggests a potential anti-inﬂammatory role for vitamin D in older English individuals from the general population.
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Low vitamin D status is an increasingly important public
health issue worldwide, in all population groups, although
more common in older adults(1). The serum concentrations
of 25-hydroxyvitamin D (25(OH)D), the major storage and
circulating form of vitamin D, rise and fall with the supply of
vitamin D3 (cholecalciferol) and vitamin D2 (ergocalciferol).
Vitamin D3 is metabolised to 25(OH)D3 in the liver by vitamin
D 25-hydroxylase and then further hydroxylated by the key
enzyme 25-hydroxylvitamin D3-1α-hydroxylase (CYP27B1) to
the biologically active form: 1,25(OH)D or calcitriol in the kid-
ney and in many different tissues throughout the body(2). Older
adults are at increased risk of poor vitamin D status due to the
lack of sun exposure and to an age-related decline in the efﬁ-
ciency of vitamin D synthesis and metabolism(3).
The importance of vitamin D in the absorption and metab-
olism of Ca for bone health is well known(2). Further studies
have demonstrated that low 25(OH)D concentrations may
promote the pathogenesis of type 1 diabetes(3), rheumatoid
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; CRP, C-reactive protein; ELSA, English Longitudinal Study of Ageing; WBC, white blood cell count.
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arthritis(4), multiple sclerosis(5), cancer(6), sarcopenia(7) and
other diseases. Other actions of vitamin D include its impact
on innate and adaptive immunity(8). High concentrations of
inﬂammatory biomarkers, such as plasma ﬁbrinogen, white
blood cell count (WBC) or C-reactive protein (CRP), have
been associated with chronic inﬂammatory diseases, such as
cardiometabolic disease risk(9). Some studies have demon-
strated that high 25(OH)D concentrations may protect against
CVD(10–12).
It is now well recognised that CYP27B1 and the vitamin D
receptor are expressed in cells involved in the inﬂammation/
immune system in the human body(13). This provides biologic-
ally plausible reasons for why low vitamin D levels could play a
role in the aetiology of inﬂammatory diseases such as cardio-
metabolic diseases but the majority showing a link are based
on small samples or on speciﬁc patient groups(14,15).
There are limited studies investigating the associations
between 25(OH)D serum levels and inﬂammatory markers
in the general population(16–18) and much of the evidence in
older adults is inconclusive. Therefore, the aim of this cross-
sectional analysis was to investigate the associations between
the 25(OH)D concentrations and three markers of inﬂamma-
tion (CRP, ﬁbrinogen and WBC) using data from the English
Longitudinal Study of Ageing (ELSA). ELSA was designed to
be nationally representative of community-dwelling adults aged
50 years and over in the general population of England, UK.
Methods
Study population
ELSA is an ongoing prospective observational study of
community-dwelling people aged 50 years and over in
England that commenced in 2002. The ELSA sample was
drawn from participants who had previously participated in
the Health Survey for England; an annual health examination
survey, which each year recruits a different nationally represen-
tative sample using a multi-staged stratiﬁed random probability
design(19). After baseline, follow-up interviews within ELSA
occur every 2 years and health examinations, i.e. a nurse
visit, every 4 years. The ﬁrst health examination was in
2004–2005. A detailed description of the study can be
found elsewhere(20). Analyses for this study used cross-
sectional data from wave 6 (2012–2013) as this was the ﬁrst
time that 25(OH)D concentrations were ascertained in
ELSA. From wave 6, 5870 participants had 25(OH)D data.
Assessment of 25-hydroxyvitamin D
Wave 6 had 10 601 respondents that also included non-core
members, such as partners. Only the 9169 core sample mem-
bers eligible for a nurse visit at which blood samples could be
taken were included. Of those, 7730 had a nurse visit. Blood
samples were obtained from 6206 participants, and 25(OH)D
concentrations were ascertained in 5870. Blood samples were
not taken from those who had a clotting or bleeding disorder
(e.g. haemophilia or low platelets), had ever had a ﬁt, were cur-
rently on anticoagulant drugs (e.g. warfarin therapy) or did not
give their consent in writing. The analyses of blood samples
were carried out at the Royal Victoria Inﬁrmary (Newcastle
upon Tyne, UK). Serum 25(OH)D levels were measured by
the Diasorin Liaison immunoassay that detects both 25(OH)
D2 and 25(OH)D3 and therefore provides the total circulating
25(OH)D level, as previously described(21). The assay for 25
(OH)D has an analytical sensitivity (lower detection limit) of
7·5 nmol/l. The detection limit represents the lowest measur-
able analyte level that can be distinguished from zero. All
assays were performed in duplicate. The CV ranged from
8·7 to 9·4 %. The laboratory performing the 25(OH)D ana-
lyses took part in the Internal and the Vitamin D External
Quality Assessment Schemes (DEQAS).
Inflammatory markers
Three inﬂammatory markers were measured at wave 6 (2012–
2013): CRP, plasma ﬁbrinogen and WBC. Further details of
the blood sample analyses, the internal quality control, and
the external quality assessment of the laboratory can be
obtained from the 2004 Health Survey for England technical
report(22) since both the Health Survey for England and
ELSA employed the same laboratory and the same guidelines
and protocols for the blood analyses.
Covariates
Total non-pension household wealth included ﬁnancial wealth
(savings and investments), the value of any home and other
property (less mortgage), the value of any business assets
and physical wealth such as artwork and jewellery, net of
debt. Wealth is the most robust indicator of socio-economic
circumstances in ELSA, and has been found to be more
strongly associated with the risk of death than any other socio-
economic position indicator at older ages(23). The number of
co-morbidities, i.e. CVD and other chronic conditions, was
assessed by self-reported doctor-diagnosed chronic diseases
that included diabetes, cancer, stroke, arthritis, lung disease,
and Parkinson’s and for CVD included high blood pressure,
angina, heart attack, heart failure, heart murmur or heart
rhythm. Smoking status was classiﬁed into non-smokers, for-
mer smokers or current smokers. Self-reported physical activ-
ity included questions about the frequency of participation in
vigorous, moderate, mild and sedentary physical activities:
more than once per week, once per week, one to three
times per month, hardly ever. Depressive symptoms were
measured by the shortened version of the Center for
Epidemiological Studies-Depression (CES-D) scale(24,25). A
dichotomous variable for depression was derived using the
validated cut point of four or more depressive symptoms to
classify depression(25). Physical functioning was measured
using self-reported limitations in the following six basic activ-
ities of daily living: dressing, walking across a room, bathing or
showering, eating, getting in or out of bed, using the toilet. A
physical functioning limitation was deﬁned as having a limita-
tion in one or more activities. Waist circumference was cate-
gorised into three main groups using sex-speciﬁc cut-offs:
low (<94 cm for men and <80 cm for women), medium
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(≥94 cm and <102 cm for men; ≥80 cm and <88 cm for
women) and high (≥102 cm for men and ≥88 cm for women).
Statistical analyses
Logistic regression was used to investigate the unadjusted and
adjusted association between 25(OH)D levels with each of the
three inﬂammatory markers. Normal levels for ﬁbrinogen
(≤3·8 g/l)(26) and CRP (<3 mg/l)(27) and below the median
for WBC (6·3 × 109 cells/l) were used as reference categories.
25(OH)D levels, the independent variable, was categorised
into quartiles: the lowest quartile (≤30 nmol/l), second quar-
tile (30·01 until 46·00 nmol/l), third quartile (46·01 until
64·00 nmol/l) and the highest quartile (>64·01 nmol/l; refer-
ence category). Following the unadjusted model (model 1), a
further four models (models 2 to 5) were derived to investigate
the association between 25(OH)D with each outcome variable
(ﬁbrinogen, CRP and WBC) and adjusted for potential con-
founders. Each subsequent model included the variables that
were included in the previous model. Model 2 adjusted for
demographic and socio-economic factors (age, sex and wealth)
and the season of the blood sampling. Model 3 further
adjusted for health behaviours; smoking and physical activity,
model 4 adjusted model 3 further for health; depression,
number of cardiovascular conditions, number of non-
cardiovascular chronic conditions and difﬁculties in activities
of daily living, and in the ﬁnal model 5, model 4 was further
adjusted for waist circumference. The analyses were per-
formed using STATA 13.0 (StataCorp LP).
Ethics approval and informed consent
All participants gave written informed consent. The National
Research Ethics Service (London Multicentre Research
Ethics Committee (MREC/01/2/91) has approved the ELSA.
Results
Of the 9169 core participants of wave 6, 25(OH)D levels in
5870 participants were ascertained. Those for whom 25(OH)
D data were available (n 5870) compared with those for
whom data were not available (n 3299) were younger; mean
age of 66·9 v. 69·4 years, with a lower proportion of females;
55·0 % v. 56·6 %, and were wealthier; 14·9 % in the lowest
quintile of wealth v. 21·1 %. Table 1 summarises the character-
istics of the sample for which 25(OH)D levels were ascer-
tained. Of the blood samples, 42 % were taken in autumn.
Of the subjects, 12 % reported depressive symptoms, and
61 and 56 % reported cardiovascular and non-cardiovascular
chronic conditions, respectively. The majority (85 %) did not
report difﬁculties in performing activities of daily living. 25
(OH)D levels ranged between 9 and 239 nmol/l and the
mean was 48·70 (SD 23·57) nmol/l. CRP levels ranged from
0·10 to 9·80 mg/l, the mean was 2·13 (SD 1·93) mg/l and
23·5 % of the sample had high levels. Plasma ﬁbrinogen levels
ranged from 1·20 to 6·30 g/l, the mean was 2·97 (SD 0·54) g/l
and 8·0 % of the respondents had levels higher than the nor-
mal. WBC ranged from 1·22 to 32·32 (×109 cells/l), the mean
was 6·51 (SD 1·96) ×109 cells/l and the median 6·30 ×109
cells/l.
In the unadjusted analyses, all three inﬂammatory markers
were associated with 25(OH)D, with low levels of 25(OH)D
being associated with higher levels of CRP, ﬁbrinogen and
WBC (Table 2). Both the lowest and the second-lowest quar-
tiles of 25(OH)D were signiﬁcantly associated with higher
levels of CRP in the unadjusted analysis (OR 1·69, 95 % CI
1·41, 2·02, P< 0·001; OR 1·34, 95 % CI 1·12, 1·61, P =
0·002; Table 2, model 1). This association remained statistically
signiﬁcant only for those in the lowest quartile even after the
adjustment for all covariates included in the models but with
attenuation in the OR from model 2 to model 5 (Table 2).
For WBC, respondents in the lowest (OR 1·73, 95 % CI
Table 1. Characteristics of the analytical sample of men and women aged
50 years and older from the English Longitudinal Study of Ageing (2012–
2013) and who had a measure of serum 25-hydroxyvitamin D
(Numbers of subjects and percentages)
Variable n %
Sex (n 5870)
Male 2640 45·0
Female 3230 55·0
Age group (years) (n 5870)
50–59 1369 23·2
60–69 2393 40·8
70–79 1542 26·3
80+ 566 9·6
Wealth (n 5752)
Lowest quintile 854 14·9
2nd quintile 1079 18·8
3rd quintile 1227 21·3
4th quintile 1274 22·2
Highest quintile 1318 22·9
Season (n 5870)
Winter 1560 26·6
Spring 437 7·4
Summer 1387 23·6
Autumn 2486 42·4
Smoking status (n 5870)
Non-smoker 2241 38·2
Former smoker 2963 50·5
Current smoker 666 11·4
Physical activity (n 5870)
Sedentary 274 4·7
Mild 870 14·8
Moderate 2828 48·2
High 1898 32·3
Depressive status (n 5819)
No 5119 88·0
Yes 700 12·0
Number of cardiovascular conditions (n 5870)
None 2264 38·6
1 1771 30·2
2+ 1835 31·3
Number of non-cardiovascular chronic conditions (n 5870)
None 2562 43·7
1 2200 37·5
2+ 1108 18·9
Difficulties in activities of daily living (n 5870)
None 4960 84·5
1+ 910 15·5
Waist circumference (n 5771)
Low 1344 23·3
Medium 1477 25·6
High 2950 51·1
3
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1·49, 2·01, P<0·001) and second-lowest (OR 1·26, 95 % CI
1·09, 1·47, P = 0·002) quartiles of 25(OH)D had a greater like-
lihood of having higher levels of white blood cells than those
in the highest quartile (Table 2, model 1). This association
remained statistically signiﬁcant even after adjustment for all
covariates included in the models but with a decline in OR
from model 2 to model 5 (Table 2). Regarding ﬁbrinogen,
only the lowest quartile of 25(OH)D was signiﬁcantly asso-
ciated with higher levels of ﬁbrinogen in the unadjusted ana-
lysis (OR 1·80, 95 % CI 1·38, 2·35, P < 0·001; Table 2,
model 1). This association remained statistically signiﬁcant
only for those in the lowest quartile but with a decline in
OR from model 2 to model 4. However, this association did
not remain signiﬁcant with adjustment by waist circumference
(model 5, Table 2), albeit that the effect estimate was of similar
magnitude to the ﬁnal model with an outcome of CRP.
Discussion
In this large, nationally representative, sample of adults aged
50 years and over, we have demonstrated that older English
adults from the general population who have low serum levels
of 25(OH)D have increased inﬂammatory biomarker proﬁles,
including increased CRP, plasma ﬁbrinogen and WBC. This
study observed signiﬁcant negative associations between 25
(OH)D and the inﬂammatory markers CRP and WBC. For
ﬁbrinogen, the association did not remain signiﬁcant in the
fully adjusted model when waist circumference was included
in the ﬁnal model. Our ﬁndings suggest that insufﬁcient 25
(OH)D levels may have the potential to affect the inﬂamma-
tory response, particularly within the older adult population.
Little research has investigated associations between low 25
(OH)D levels and inﬂammatory markers in the general
population, especially in apparently healthy older adults.
Most of the previous studies have been conducted in young
adults with chronic inﬂammatory conditions, and controversy
remains about the optimal serum 25(OH)D levels for health in
older age. In addition, the results from studies investigating the
associations between 25(OH)D concentrations with CRP or
ﬁbrinogen concentrations are conﬂicting and studies on the
association between 25(OH)D concentrations and WBC are
rare(28). Nevertheless, we cannot ignore that low 25(OH)D
levels could represent a marker of ill health resulting from
inﬂammatory processes, a hypothesis that has been raised
from a very recent systematic review documenting a discrep-
ancy between the existing observational and intervention stud-
ies on the role of 25(OH)D concentrations in non-skeletal
health outcomes(29).
In the present study, CRP levels showed signiﬁcant negative
associations with 25(OH)D levels. Limited data from observa-
tional studies(18,30–35) lend support to a primary anti-
inﬂammatory role of vitamin D. In a very recent observational
investigation conducted in 957 older Irish adults (>60 years of
age), Laird et al.(32) showed a signiﬁcant association between
low vitamin D status (25(OH)D < 25 nmol/l) and markers
of inﬂammation including IL-6, TNF-α, IL-10, CRP and the
ratio of IL-6 to IL-10. Yet, not all epidemiological studies
reported linear inverse associations between the measures.
Shea et al.(34) studied the relationship of vitamin D with several
inﬂammatory markers cross-sectionally in 1381 subjects from
the Framingham Offspring Study cohort and did not ﬁnd a
signiﬁcant association for most of the markers, including
CRP. Another, smaller study by Michos et al.(17) did also not
ﬁnd a signiﬁcant association between vitamin D and CRP.
Evidence from an interventional study investigating the
effect of vitamin D supplementation on selected inﬂammatory
Table 2. Unadjusted and multivariable logistic regression investigating the association between 25-hydroxyvitamin D (25(OH)D) concentrations with
inflammatory markers†
(Odds ratios and 95 % confidence intervals)
Model 1 (unadjusted) Model 2 Model 3 Model 4 Model 5
OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI OR 95 % CI
C-reactive protein
25(OH)D
Highest quartile 1 – 1 – 1 – 1 – 1 –
3rd quartile 1·17 0·97, 1·40 1·16 0·96, 1·40 1·15 0·95, 1·39 1·16 0·96, 1·40 1·06 0·87, 1·29
2nd quartile 1·34* 1·12, 1·61 1·32* 1·10, 1·60 1·28* 1·06, 1·55 1·27* 1·04, 1·53 1·11 0·91, 1·35
Lowest quartile 1·69* 1·41, 2·02 1·59* 1·31, 1·93 1·42* 1·17, 1·73 1·43* 1·17, 1·75 1·23* 1·00, 1·51
Fibrinogen
25(OH)D
Highest quartile 1 – 1 – 1 – 1 – 1 –
3rd quartile 1·09 0·81, 1·46 1·06 0·79, 1·43 1·06 0·79, 1·42 1·05 0·78, 1·41 0·98 0·73, 1·33
2nd quartile 1·04 0·77, 1·40 1·03 0·76, 1·39 0·98 0·72, 1·33 0·95 0·70, 1·29 0·85 0·62, 1·16
Lowest quartile 1·80* 1·38, 2·35 1·66* 1·25, 2·22 1·40* 1·04, 1·87 1·37* 1·02, 1·84 1·22 0·90, 1·66
White blood cell count
25(OH)D
3rd quartile 1·17* 1·01, 1·35 1·13 0·98, 1·32 1·12 0·96, 1·31 1·14 0·98, 1·33 1·09 0·93, 1·28
2nd quartile 1·26* 1·09, 1·47 1·26* 1·08, 1·46 1·18* 1·01, 1·39 1·19* 1·01, 1·40 1·11 0·94, 1·31
Lowest quartile 1·73* 1·49, 2·01 1·70* 1·45, 2·00 1·44* 1·22, 1·72 1·45* 1·22, 1·72 1·35* 1·13, 1·60
* P < 0.001.
† Model 1: 25(OH)D (unadjusted). Model 2: model 1 + adjusted for sex, age group, wealth, and season. Model 3: model 2 + adjusted for smoking, and physical exercise. Model 4:
model 3 + adjusted for depression, number of cardiovascular conditions, number of non-cardiovascular conditions, and difficulties in activities of daily living. Model 5: model 4 +
adjusted for waist circumference.
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biomarkers in older adults using secondary data from a rando-
mised, placebo-controlled trial found little evidence of an
effect of vitamin D supplementation on cytokine or adipokine
levels, with the possible exception of IL-6(35). A recent
study(36), investigating the association between serum 25
(OH)D and CRP and a potential causal effect by using genetic
variants in bi-directional Mendelian randomisation analysis, in
the Rotterdam Study, a prospective population-based cohort,
showed that serum vitamin D was inversely associated with
CRP. However, the results from the Mendelian randomisation
analyses did not provide evidence for a causal association.
A possible reason for the lack of correlation between 25
(OH)D and CRP in some studies was that they contained
younger participants that may have diluted the effect estimate
while older participants were not investigated separately.
Indeed, ageing itself is associated with low-grade chronic
inﬂammation and elevated CRP and in light of the aforemen-
tioned associations with 25(OH)D status, a stronger effect of
25(OH)D may thus be more distinctly observed in the elderly
compared with younger individuals in whom CRP levels are
expectedly lower(37).
Our ﬁndings showed that ﬁbrinogen did not maintain its
negative association with 25(OH)D levels when waist circum-
ference was included in the ﬁnal model. Similarly, a large study
that included 6538 individuals from the 1958 British Birth
Cohort(38) found an inverse association between 25(OH)D
and ﬁbrinogen in analyses adjusted for sex and month of
blood draw. Yet, these associations vanished after additional
adjustment for obesity, lifestyle and social characteristics. As
with CRP, previous studies revealed conﬂicting results regard-
ing the association between 25(OH)D and ﬁbrinogen(39,40).
The conﬂicting results are probably due to differences in
study design and the selection of speciﬁc patient groups. In
contrast to the studies that reported no association between
the measures, several studies reported an inverse relationship
between 25(OH)D and ﬁbrinogen concentrations(28).
Studies investigating the relationship between 25(OH)D and
WBC are sparse. WBC in the present analyses showed a sig-
niﬁcant inverse association with 25(OH)D. Similarly, one
recent study(28) examining the associations of 25(OH)D with
high-sensitivity CRP, ﬁbrinogen and WBC in 2723 men and
women aged 25 to 88 years from the ﬁrst follow-up of the
Study of Health in Pomerania also conﬁrmed a potential
role of 25(OH)D in chronic inﬂammation. The authors
observed beneﬁcial effects of increasing 25(OH)D for ﬁbrino-
gen and WBC (in smokers only). On the other hand, a study
assessing the relationship between 25(OH)D and WBC in a
large hospital population including 1557 adult subjects without
chronic kidney disease and 340 adult patients with chronic kid-
ney disease showed no association between the two measures,
in adults with or without chronic kidney disease(41).
Our study has several strengths and potential limitations that
need to be considered. A major strength is the large and rep-
resentative sample of community-dwelling English men and
women aged 50 years and older. In addition, certiﬁed exami-
ners following standardised protocols, assuring excellent qual-
ity of data, performed all examinations and laboratory
measurements. Limitations arise from the cross-sectional
study design, which investigates associations but cannot pro-
vide evidence of causality. However, ELSA is planning to
measure levels of vitamin D again in its eighth wave (2016–
2017) which will enable longitudinal analyses utilising these
repeated measures. Our analyses are based on single-occasion
biomarker measurements, which might not adequately
represent the participants’ inﬂammatory status. Additionally,
we were unable to assess differences between vitamin D2
and vitamin D3, as the respective data were not available in
ELSA. The status on treatment with anti-inﬂammatory
drugs was not documented in our study group. However,
even without taking this into account, in our cohort we
show an inverse correlation between CRP and 25(OH)D in
different groups that is consistent and in agreement with
other reports, which similarly also did not correct for this vari-
able. Finally, it was not possible to explore the effect of ethni-
city in our analysis, which might act as a confounder due to
potentially different rates of inﬂammatory disease in different
ethnic groups, since 98 % of ELSA participants are white
English.
In summary, our study suggests a potential role of 25(OH)D
in chronic inﬂammation. Our ﬁndings, therefore, contribute
signiﬁcantly to the body of evidence supporting a role for vita-
min D in inﬂammatory conditions. Controversy exists as to
whether vitamin D lowers inﬂammation or whether inﬂamma-
tion lowers 25(OH)D concentrations. Whether our ﬁndings
have any clinical meaning needs to be further evaluated in ran-
domised controlled clinical trials, especially the potential
effects of vitamin D supplementation.
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